Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 20/20 | 0.76 |
| ▸ | PDE4A | P27815 | 18/20 | 0.76 |
| ▸ | PDE4C | Q08493 | 18/20 | 0.76 |
| ▸ | PDE4D | Q08499 | 18/20 | 0.76 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15908883 | 0.91 | PDE4B (0.77) | PDE4BPDE4APDE4CPDE4DABCB11 | |
| SCHEMBL12316203 | 0.88 | PDE4B (0.81) | PDE4BPDE4APDE4CPDE4DABCB11 | |
| Roflumilast SCHEMBL19158 | 0.86 | PDE4B (1.00) | PDE4BPDE4APDE4CPDE4DABCB11 | |
| Roflumilast SCHEMBL18095182 | 0.86 | PDE4B (1.00) | PDE4BPDE4APDE4CPDE4DABCB11 | |
| Roflumilast SCHEMBL29349467 | 0.86 | PDE4B (1.00) | PDE4BPDE4APDE4CPDE4DABCB11 | |
| Roflumilast SCHEMBL29033058 | 0.85 | PDE4B (0.98) | PDE4BPDE4APDE4CPDE4DABCB11 | |
| Roflumilast SCHEMBL29039838 | 0.85 | PDE4B (0.98) | PDE4BPDE4APDE4CPDE4DABCB11 | |
| Roflumilast SCHEMBL28150332 | 0.85 | PDE4B (0.98) | PDE4BPDE4APDE4CPDE4DABCB11 | |
| Roflumilast SCHEMBL29191360 | 0.85 | PDE4B (0.96) | PDE4BPDE4APDE4CPDE4DABCB11 | |
| Roflumilast SCHEMBL20677818 | 0.85 | PDE4B (0.96) | PDE4BPDE4APDE4CPDE4DABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 736 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111904962-A | Pharmaceutical composition containing PDE4 inhibitor and PI3 or dual PI 3-gamma kinase inhibitor | 理森制药股份公司 | 2020-11-10 | — | — | CN | claimed |
| US-20200237735-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A PDE4 INHIBITOR AND A P13 DELTA OR DUAL P13 DELTA-GAMMA KINASE INHIBITOR | RHIZEN PHARMACEUTICALS AG (CH) | 2020-07-30 | — | — | US | claimed |
| US-10058539-B2 | Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor | RHIZEN PHARMACEUTICALS SA (CH) | 2018-08-28 | — | — | US | claimed |
| US-20170319558-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A PDE4 INHIBITOR AND A PI3 DELTA OR DUAL PI3 DELTA-GAMMA KINASE INHIBITOR | RHIZEN PHARMACEUTICALS AG (CH) | 2017-11-09 | — | — | US | claimed |
| US-9737521-B2 | Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor | RHIZEN PHARMACEUTICALS SA (CH) | 2017-08-22 | — | — | US | claimed |
| US-20150272936-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A PDE4 INHIBITOR AND A PI3 DELTA OR DUAL PI3 DELTA-GAMMA KINASE INHIBITOR | RHIZEN PHARMACEUTICALS AG (CH) | 2015-10-01 | — | — | US | claimed |
| EP-2916868-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A PDE4 INHIBITOR AND A PI3 DELTA OR DUAL PI3 DELTA-GAMMA KINASE INHIBITOR | Rhizen Pharmaceuticals S.A. (CH) | 2015-09-16 | — | — | EP | claimed |
| WO-2014072937-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A PDE4 INHIBITOR AND A PI3 DELTA OR DUAL PI3 DELTA-GAMMA KINASE INHIBITOR | RHIZEN PHARMACEUTICALS SA (CH) | 2014-05-15 | — | — | WO | claimed |
| EP-1628682-B1 | COMPOSITION COMPRISING A PDE4 INHIBITOR AND A PDE5 INHIBITOR FOR THE TREATMENT OF COPD | TAKEDA GMBH (DE) | 2013-09-25 | — | — | EP | claimed |
| EP-2598145-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF RESPIRATORY AND INFLAMMATORY DISEASES | Boehringer Ingelheim International GmbH (DE) | 2013-06-05 | — | — | EP | claimed |
| WO-2004084894-A1 | SYNERGISTIC COMBINATION COMPRISING ROFLUMILAST AND REVATROPATE FOR THE TREATMENT OF RESPIRATORY DISEASES | ALTANA PHARMA AG (DE) | 2004-10-07 | — | — | WO | claimed |
| WO-2004084897-A1 | SYNERGISTIC COMBINATION COMPRISING ROFLUMILAST AND AN ANTICHOLINERGIC AGENT SELECTED FROM IPRATROPIUM, OXITROPIUM AND TIOTROPIUM SALTS FOR THE TREATMENT OF RESPIRATORY DISEASES | ALTANA PHARMA AG (DE) | 2004-10-07 | — | — | WO | claimed |
| WO-2004084896-A1 | SYNERGISTIC COMBINATION COMPRISING ROFLUMILAST AND AN ANTICHOLINERGIC AGENT SELECTED FROM IPRATROPIUM, OXITROPIUM AND TIOTROPIUM SALTS FOR THE TREATMENT OF RESPIRATORY DISEASES | ALTANA PHARMA AG (DE) | 2004-10-07 | — | — | WO | claimed |
| WO-2004062671-A2 | PDE4 INHIBITORS FOR THE TREATMENT OF NEOPLASMS OF LYMPHOID CELLS | ALTANA PHARMA AG (DE) | 2004-07-29 | — | — | WO | claimed |
| US-20040058950-A1 | Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-25 | — | — | US | claimed |
| WO-2004004704-A1 | NOVEL PHARMACEUTICAL COMPOSITIONS COMPRISING NOVEL ANTICHOLINERGIC AGENTS AND PDE-IV INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-01-15 | — | — | WO | claimed |
| US-6531493-B1 | 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)benzamide in the treatment of multiple sclerosis | ALTANA PHARMA AG (DE) | 2003-03-11 | — | — | US | claimed |
| JP-2002538207-A | — | — | 2002-11-12 | — | — | JP | claimed |
| EP-1161239-A2 | 3-CYCLOPROPYLMETHOXY-4-DIFLUOROMETHOXY-N-(3,5-DICHLOROPYRID-4-YL)BENZAMIDE IN THE TREATMENT OF MULTIPLE SCLEROSIS | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2001-12-12 | — | — | EP | claimed |
| WO-2000053182-A2 | 3-CYCLOPROPYLMETHOXY-4-DIFLUOROMETHOXY-N-(3,5-DICHLOROPYRID-4-YL)BENZAMIDE IN THE TREATMENT OF MULTIPLE SCLEROSIS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-09-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058950-A1 | Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors | PDE4B, PDE4A, PDE3B | PDE4B 1/4885PDE4A 2/4885PDE4C 4/4885 |
| US-20170319558-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A PDE4 INHIBITOR AND A PI3 DELTA OR DUAL PI3 DELTA-GAMMA KINASE INHIBITOR | PIK3CD, PIK3R4, PIK3CG | PDE4B 6/4885PDE4A 5/4885PDE4C 10/4885 |
| US-20200237735-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A PDE4 INHIBITOR AND A P13 DELTA OR DUAL P13 DELTA-GAMMA KINASE INHIBITOR | PDE4A, PDE12, PDE4B | PDE4B 3/4885PDE4A 1/4885PDE4C 8/4885 |
| US-20150272936-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A PDE4 INHIBITOR AND A PI3 DELTA OR DUAL PI3 DELTA-GAMMA KINASE INHIBITOR | PIK3CD, PIK3R4, PIK3CG | PDE4B 6/4885PDE4A 5/4885PDE4C 10/4885 |
| US-10058539-B2 | Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor | PIK3CD, PIK3R4, PIK3CG | PDE4B 6/4885PDE4A 5/4885PDE4C 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.